Lung capacity is a determinant of cardiovascular disease and myocardial infarction
Authors:
Open Access
- 13 January 2026
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Abstract
Introduction: There is growing evidence suggesting that lung capacity is associated with risk of cardiometabolic disease. However, most studies rely on spirometric measures of lung capacity and self-reported cardiometabolic disease. We aimed to investigate the association of total lung capacity (TLC) with cardiometabolic disease defined using ICD-10 codes. Methods: Data from adult patients referred to Cambridge University Hospitals between 2016 and 2024 were used if spirometry, single breath gas transfer, and body plethysmography were performed in the same session. GLI reference equations were used to generate z-scores for lung function measures. ICD-10 codes for cardiovascular disease, hypertension, and diabetes were extracted from medical records. We used multi-level (mixed-effects) Cox regression analysis to investigate the association between lung function measurements and incident cardiometabolic disease. Results: 5628 patients were included, 51% were female, with a median age of 62 (IQR 50–70) years. 60% reported a smoking history. Mean follow-up time was 5.7 (SD 2.3) years, during which time 5% received a cardiovascular disease code, 7% a hypertension code, and 3% a diabetes code. A 1-unit increment in TLC z-score was associated with a 12% lower risk of cardiovascular disease (HR: 0.88, 95%CI 0.80–0.97) later in life. The same was seen for FVC (HR: 0.88, 95%CI 0.77–0.99) but not FEV 1 /FVC or DLCO. A larger TLC was also associated with lower risk of myocardial infarction. We found no association of lung function measures with incident hypertension or diabetes. Conclusion: Lung capacity is a determinant for cardiovascular disease and myocardial infarction, with larger lungs being protective. TLC and FVC should be considered by clinicians along with other factors, when evaluating a person’s risk of cardiovascular disease.Keywords
Funding Information
- Asthma and Lung UK (DJF25\28)
- Imperial-ARUA Research Seed Fund
This publication has 31 references indexed in Scilit:
- Trends in population attributable fraction of modifiable risk factors for cardiovascular diseases across three decadesEuropean Journal of Preventive Cardiology, 2024
- Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Small lung syndrome: the need to reclassify chronic lung diseaseThe Lancet Respiratory Medicine, 2023
- Role of Pulmonary Function in Predicting New-Onset Cardiometabolic Diseases and Cardiometabolic MultimorbidityChest, 2022
- Ten things to know about ten cardiovascular disease risk factorsAmerican Journal of Preventive Cardiology, 2021
- Declining Lung Function and Cardiovascular RiskJACC, 2018
- Systemic inflammatory markers in relation to lung function in NHANES. 2007–2010Respiratory Medicine, 2018
- Association of pulse wave velocity with total lung capacity: A cross-sectional analysis of the BOLD London studyRespiratory Medicine, 2015
- Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort studyJournal of Internal Medicine, 2003
- Vital capacity as a predictor of cardiovascular disease: The Framingham studyAmerican Heart Journal, 1983